Company Registration No. 09485187 (England and Wales)
Noxsudor Therapeutics Limited
Unaudited accounts
for the year ended 31 March 2017
Noxsudor Therapeutics Limited
Unaudited accounts
Contents
Noxsudor Therapeutics Limited
Company Information
for the year ended 31 March 2017
Directors
H L Oakes Jnr
D J Macfarlane
T M Steel
Company Number
09485187 (England and Wales)
Registered Office
26 GROSVENOR STREET
LONDON
ENGLAND
W1K 4QW
UNITED KINGDOM
Accountants
Dunnell Accounting
49 Mandeville Close
Vanbrugh Park
Blackheath
London
SE3 7AH
Noxsudor Therapeutics Limited
Statement of financial position
as at
31 March 2017
Cash at bank and in hand
9,942
24,871
Creditors: amounts falling due within one year
(495)
(660)
Net current assets
9,447
51,330
Called up share capital
1,917
1,917
Share premium
202,450
202,450
Profit and loss account
(194,920)
(153,037)
Shareholders' funds
9,447
51,330
For the year ending 31 March 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
Approved by the Board on 8 February 2018.
H L Oakes Jnr
Director
Company Registration No. 09485187
Noxsudor Therapeutics Limited
Notes to the Accounts
for the year ended 31 March 2017
Noxsudor Therapeutics Limited is a private company, limited by shares, registered in England and Wales, registration number 09485187. The registered office is 26 GROSVENOR STREET, LONDON, ENGLAND, W1K 4QW, UNITED KINGDOM.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
These financial statements for the year ended
31 March 2017 are the first financial statements that comply with FRS 102 Section 1A Small Entities. The date of transition is 1 April 2015.
The transition to FRS 102 Section 1A Small Entities has resulted in a small number of changes in accounting policies to those used previously.
The nature of these changes and their impact on opening equity and profit for the comparative period are explained in note
7 below.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
5
Creditors: amounts falling due within one year
2017
2016
6
Average number of employees
During the year the average number of employees was 0 (2016: 0).
Noxsudor Therapeutics Limited
Notes to the Accounts
for the year ended 31 March 2017
7
Reconciliations on adoption of FRS 102
Reconciliation of equity
1 April 2015
31 March 2016
Capital and reserves (as previously stated)
-
33,906
Restatement of VAT account
-
17,424
Capital and reserves (as restated)
-
51,330
Reconciliation of profit or loss for the year
31 March 2016
Profit for the year (as previously stated)
(170,461)
Restatement of VAT account
17,424
Profit for the year (as restated)
(153,037)